Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use
March 5, 2021 - Johnson & Johnson (the Company) announced today that Health Canada has granted an Interim Order (IO) authorization for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.This decision was based on scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.Johnson & Johnson anticipa...
Source: Johnson and Johnson - March 5, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
NIDCR Science News - March 2021
Having trouble viewing this email? View it as a Web page.
A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH.
A Search for Cell Identity
NIDCR's Dr. Roxane Tussiwand studies how immune cells are shaped by their surroundings
NIDCR • February 22, 2021
The Scarred Villain: Study Explores Neurocognitive Basis of Bias Against People Who Look DifferentUniversity of Pennsylvania • February 12, 2021
Study Reveals Cause of Comm...
Source: NIDCR Science News - March 2, 2021 Category: Dentistry Source Type: news
Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe today’s re...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., February 26, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial. “We are extremely gratefu...
Source: Johnson and Johnson - February 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Scientists reveal details of antibodies that work against Zika virus
(Biophysical Society) The Zika outbreak of 2015 and 2016 is having lasting impacts on children whose mothers became infected with the virus while they were pregnant. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 25, 2021 Category: Infectious Diseases Source Type: news
Models to predict dengue, zika and yellow fever outbreaks are developed by researchers
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) Scientists will monitor areas in which these diseases are endemic, such as S ã o Paulo, the Amazon, the Pantanal and Panama, to investigate the factors that trigger outbreaks (monkey being examined in Manaus á rea. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2021 Category: International Medicine & Public Health Source Type: news
Scientists use machine-learning approach to track disease-carrying mosquitoes
(Utah State University) A team of researchers from Utah State University, University of California, Davis and Yale University are using a machine-learning approach to map landscape connectivity of the species Aedes aegypti, the so-called Yellow Fever mosquito, which is a primary vector for transmission of viruses causing dengue fever, chikungunya and Zika. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 22, 2021 Category: Biology Source Type: news
Zika Vaccine Candidate Shows Promise in Phase 1 Trial Zika Vaccine Candidate Shows Promise in Phase 1 Trial
A Zika virus vaccine candidate prompted antibody responses in 80% of individuals who received two doses in a phase 1 study.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - February 19, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 19, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered today includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The Company’s rolling submission of clinical data to WHO is now complete.“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our unwavering co...
Source: Johnson and Johnson - February 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 16, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen-Cilag International N.V., has submitted a conditional Marketing Authorisation Application (cMAA) to the European Medicines Agency (EMA) seeking authorisation for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial.“Throughout Europe, there remains an urgent need for additional COVID-19 vaccines, and today’s submission is a significant step forward in ensuring the European Union has anot...
Source: Johnson and Johnson - February 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Drought restrictions had side benefit: Lowering risk of mosquito-borne disease
Shallow pools of water on lawns are ideal breeding grounds for the mosquitoes that transmit West Nile virus, the most common mosquito-borne disease in the United States.A new study by scientists from UCLA and three other universities found that reducing shallow pools of water where the insects lay their eggs is key to preventing the spread of the virus.The study, funded by a grant from the UC Office of the President and published in the journal Environmental Science and Technology, found that California ’s water-use restrictions during the statewide drought from 2012 to 2016 led to a decrease in the number of mosquitoes ...
Source: UCLA Newsroom: Health Sciences - February 16, 2021 Category: Universities & Medical Training Source Type: news
Zika vaccine shows promise in early trials
A vaccine against Zika produced immunity to the mosquito-borne virus for up to a year in at least 80% of those who received it, a study published Monday by the Annals of Internal Medicine found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 15, 2021 Category: Consumer Health News Source Type: news
Zika vaccine candidate shows promise in phase I trial
(American College of Physicians) The Zika virus candidate, Ad26.ZIKV.001, a replication-incompetent human adenovirus serotype 26 (ad26) vector showed promising safety and immunogenicity in a phase I clinical trial. Researchers say the vaccine warrants further development should the need reemerge. The findings are published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 15, 2021 Category: Infectious Diseases Source Type: news
International Women's Day Panel on diversity in health evidence synthesis - 8 March 2021
International Women ' s Day is March 8th! Join us as we discuss and highlight minority women and young investigators working in health science and evidence synthesis. Hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis. Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis. In the past it ' s been the ' Ann Anderson Walk ' at the Cochrane Colloquium to raise money for theannual A...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news
